On the contrary, modulating PAD-associated pathways more specifically, i.e., factor Xa-inhibition (as mentioned above, the role of coagulation factors in the establishment of PAD has been demonstrated with GWAS) (37) has a great impact on reducing MACE in PAD patients as demonstrated by positive results of two recent large clinical outcome studies (COMPASS and VOYAGER PAD) (43, 44). Here, F10 is linked to peripheral arterial disease.